# DYAI (DYAI)

> Source: Nexqual · https://nexqual.com/DYAI · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, DYAI (DYAI), nexqual.com/DYAI" · informational, not investment advice.

**Price:** USD 0.42 (+2.09% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 0.42 · day 0.4–0.48 · 52w 0.34–1.6 · market cap null · NCM

## Key facts
- Total return with dividends: 1Y -60.0% vs S&P 500 +18.1%; 5Y -91.3% vs S&P 500 +85.1%.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -60.0% | -91.3% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -60.1% | -38.6% |
| Volatility (annualized) | 83.5% | 70.3% |
| Max drawdown | -72.8% (Jul 2026→Sep 2026) | -91.3% (Oct 2021→Oct 2026) |

## Peers
FULC (Fulcrum Therapeutics, Inc.) USD 3.67 -0.27% · BYSI (BeyondSpring, Inc.) USD 0.58 -4.14% · DMAC (DiaMedica Therapeutics Inc.) USD 8.04 +2.81% · IPHA (Innate Pharma S.A.) USD 1.48 +0.68% · EDSA (Edesa Biotech, Inc.) USD 2.67 -6.32%

## More
Full page: https://nexqual.com/DYAI · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt